
Opinion|Videos|July 31, 2024
Examining Toxicity Management of BTK Inhibitors for CLL/SLL
Author(s)Mazyar Shadman, MD, MPH
Mazyar Shadman, MD, MPH, discusses the safety profile of BTK inhibitors in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What safety concerns do you have for using BTK inhibitors in patients with CLL/SLL?
- What notable toxicities are demonstrated in the latest clinical data?
- How do you manage those toxicities in your practice?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















